NCT00234741View on ClinicalTrials.gov

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2005

Conditions
Crohn's Disease
Interventions
DRUG

STA-5326 mesylate

Trial Locations (1)

20892

Nih/Niaid, Bethesda

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Synta Pharmaceuticals Corp.

INDUSTRY

NCT00234741 - Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter